X4 Pharmaceuticals(NASDAQ) XFOR

X4 Pharmaceuticals, Inc. treats people with rare blood diseases. Its treatments help patients whose bodies cannot fight infections. The company makes drugs to help white blood cells.

Pills for Rare Diseases

• XOLREMDI: Daily oral pill for patients 12 years of age and older with WHIM syndrome; increases mature white blood cell counts in the blood.
• Chronic Neutropenia Candidate: Experimental therapy in Phase 3 testing for people with low neutrophil levels who face frequent infections.
• CXCR4 Antagonists: Small-molecule drugs that target a specific receptor to regulate the release of immune cells from the bone marrow.

Steps Toward Global Expansion

• Received European Commission marketing authorization for XOLREMDI in the European Union on April 29, 2026.
• Transferred the European marketing authorization to Norgine in July 2026 for commercialization in Europe, Australia, and New Zealand.
• Transitioned management of the 4WARD Phase 3 clinical trial to a premiere clinical research organization to support enrollment.
• Secured Fast Track designation from the FDA for mavorixafor to treat chronic neutropenia.
• Partnered with Abbisko Therapeutics for the distribution and manufacturing of XOLREMDI in China and surrounding regions.

A Specific Clinical Focus

The company uses a licensing model to distribute its approved therapy across global markets like Europe and Asia while focusing internal resources on clinical trials. Its core expertise lies in targeting the CXCR4 receptor to manage rare immune system disorders.

Performance by the Numbers

• Total revenue was $8.8 million for the three months ended June 30, 2026, compared to $2.0 million in the same period of the prior year.
• Net product sales were $4.8 million for the six months ended June 30, 2026, up from $2.7 million in the previous year.
• Research and development expenses were $30.5 million for the six months ended June 30, 2026, down from $36.9 million year over year.
• Cash, cash equivalents, and restricted cash reached $195.8 million as of June 30, 2026.

The Path Forward

X4 Pharmaceuticals has transitioned from a research-focused firm to a commercial-stage company with an approved therapy for rare immune disorders. It continues to balance drug sales with late-stage clinical trials to expand its reach in the hematology market.